Evelo dealt an­oth­er blow with a PhII fail, plans for strate­gic al­ter­na­tives

Evelo Bio­sciences is ex­plor­ing strate­gic al­ter­na­tives for its mid-stage pso­ri­a­sis treat­ment af­ter it re­port­ed that an­oth­er pso­ri­a­sis drug failed a Phase II clin­i­cal tri­al. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER